Oric Pharmaceuticals Inc.(ORIC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ORIC Oric Pharmaceuticals Inc.

盘后交易 05-19 19:15:32 EDT

7.97

+0.04

+0.50%

盘后8.00

+0.03+0.38%

18:26 EDT

最高8.10	最低7.68	成交量82.47万
今开7.88	昨收7.93	日振幅5.30%
总市值8.25亿	流通市值5.64亿	总股本1.04亿
成交额656.04万	换手率1.17%	流通股本7,073万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ORIC","market":"US","secType":"STK","nameCN":"Oric Pharmaceuticals Inc.","latestPrice":7.97,"timestamp":1779220800000,"preClose":7.93,"halted":0,"volume":824742,"hourTrading":{"tag":"盘后","latestPrice":8,"preClose":7.97,"latestTime":"18:26 EDT","volume":17617,"amount":140564.3059638,"timestamp":1779229619539,"change":0.03,"changeRate":0.003764,"amplitude":0.035132},"delay":0,"changeRate":0.00504413619167718,"floatShares":70726400,"shares":103517562,"eps":-1.402607,"marketStatus":"盘后交易","change":0.04,"latestTime":"05-19 19:15:32 EDT","open":7.88,"high":8.1,"low":7.68,"amount":6560444.878164,"amplitude":0.052963,"askPrice":9.22,"askSize":100,"bidPrice":7.31,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.402607,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1779235200000},"marketStatusCode":4,"adr":0,"listingDate":1587700800000,"exchange":"NASDAQ","adjPreClose":7.93,"preHourTrading":{"tag":"盘前","latestPrice":7.8,"preClose":7.93,"latestTime":"09:08 EDT","volume":13225,"amount":104431.484935,"timestamp":1779196130952,"change":-0.13,"changeRate":-0.016393,"amplitude":0.044136},"postHourTrading":{"tag":"盘后","latestPrice":8,"preClose":7.97,"latestTime":"18:26 EDT","volume":17617,"amount":140564.3059638,"timestamp":1779229619539,"change":0.03,"changeRate":0.003764,"amplitude":0.035132},"volumeRatio":0.532349,"impliedVol":1.4376,"impliedVolPercentile":0.9283},"requestUrl":"/m/hq/s/ORIC","defaultTab":"news","newsList":[{"id":"1102563295","title":"Oric Pharmaceuticals：继续评估Rinzimetostat在前列腺癌及其他适应症中的新应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1102563295","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102563295?lang=zh_cn&edition=full","pubTime":"2026-04-01 04:08","pubTimestamp":1774987691,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. 宣布，公司将进一步评估其候选药物Rinzimetostat在更多适应症中的应用潜力，重点聚焦于前列腺癌领域，并探索其在其他疾病治疗中的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128071770","title":"Oric Pharmaceuticals预计首个三期试验Himalayas-1将于2026年上半年启动，针对阿比特龙治疗后MCRPC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1128071770","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128071770?lang=zh_cn&edition=full","pubTime":"2026-04-01 04:08","pubTimestamp":1774987691,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. 宣布，其首个三期临床试验——代号为Himalayas-1的研究——预计将在2026年上半年正式启动。该试验将专注于治疗转移性去势抵抗性前列腺癌（MCRPC）患者，这些患者先前已接受过阿比特龙的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194789949","title":"Oric Pharmaceuticals宣布Rinzimetostat Rp3d联合Darolutamide入选Himalayas-1三期全球研究，剂量优化数据支持其潜在同类最优疗法前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1194789949","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194789949?lang=zh_cn&edition=full","pubTime":"2026-04-01 04:08","pubTimestamp":1774987682,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals宣布，其研发的Rinzimetostat Rp3d联合Darolutamide治疗方案已正式入选Himalayas-1三期全球临床研究。最新剂量优化研究数据进一步佐证了该疗法可能具备同类最优的疾病治疗潜力。这项重要进展标志着Oric Pharmaceuticals在肿瘤治疗领域的创新探索迈入关键阶段。Himalayas-1三期研究将聚焦于评估该联合疗法在特定患者群体中的综合疗效。全球多中心的研究设计有望加速数据收集进程，为潜在的新药申报提供关键支撑。此次剂量优化数据的披露，凸显了Rinzimetostat Rp3d在复杂治疗方案中的独特价值定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120477884","title":"Oric Pharmaceuticals将公布Rinzimetostat治疗MCRPC患者1B期试验联合剂量优化数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1120477884","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120477884?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:32","pubTimestamp":1774614720,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. 即将公布其药物Rinzimetostat在转移性去势抵抗性前列腺癌（MCRPC）患者中开展的1B期临床试验的联合剂量优化数据。该数据旨在评估Rinzimetostat与其他药物联合使用时的最佳剂量方案，为后续临床开发提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127945858","title":"Oric Pharmaceuticals拟通过Jefferies不定期发售至多2亿美元普通股——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1127945858","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127945858?lang=zh_cn&edition=full","pubTime":"2026-02-24 06:26","pubTimestamp":1771885572,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新披露的文件，生物制药公司Oric Pharmaceuticals Inc.（ORIC）宣布已启动一项股权发行计划。该公司将授权通过承销商Jefferies，在未来适时向市场不定期发售普通股股票，总筹资规模最高可达2亿美元。\n此类\"暂搁发行\"安排为上市公司提供了灵活的融资渠道，使其能够根据市场条件和资金需求分批发行股票。此次融资计划将助力Oric Pharmaceuticals推进其肿瘤靶向治疗药物的研发管线。通过Jefferies作为销售代理，公司可更高效地把握市场窗口期优化融资结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593734104","title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593734104","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593734104?lang=zh_cn&edition=full","pubTime":"2025-12-25 06:00","pubTimestamp":1766613621,"startTime":"0","endTime":"0","summary":"杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385521.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ORIC","SLDB","TYRA","LENZ","TSHA","TNGX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1117121799","title":"Oric® Pharmaceuticals在2025年ESMO亚洲大会上宣布Enozertinib（Oric-114）关于EGFR非典型和EGFR外显子20非小细胞肺癌的最新口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1117121799","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117121799?lang=zh_cn&edition=full","pubTime":"2025-12-04 05:02","pubTimestamp":1764795742,"startTime":"0","endTime":"0","summary":"Oric® Pharmaceuticals在2025年ESMO亚洲大会上宣布Enozertinib（Oric-114）关于EGFR非典型和EGFR外显子20非小细胞肺癌的最新口头报告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128963466","title":"Oric Pharmaceuticals第三季度净收入为-3258.7万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1128963466","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128963466?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:45","pubTimestamp":1763574350,"startTime":"0","endTime":"0","summary":"11月13日 - Oric Pharmaceuticals第三季度运营支出为3667.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189416261","title":"Oric Pharmaceuticals公布根据纳斯达克上市规则5635(C)(4)的诱因授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1189416261","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189416261?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:13","pubTimestamp":1763572428,"startTime":"0","endTime":"0","summary":"Oric Pharmaceuticals Inc. ::*ORIC PHARMACEUTICALS公布根据纳斯达克上市规则5635(C)(4)的诱因授予","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187798230","title":"Oric® Pharmaceuticals宣布Oric-944 1B期临床试验剂量探索部分完成，并持续展现潜在的最佳疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=1187798230","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187798230?lang=zh_cn&edition=full","pubTime":"2025-11-14 05:06","pubTimestamp":1763067973,"startTime":"0","endTime":"0","summary":"Oric® Pharmaceuticals宣布Oric-944 1B期临床试验的剂量探索部分已完成，并继续展现出潜在的最佳疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518755942","title":"Oric Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518755942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518755942?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:31","pubTimestamp":1741617117,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时31分，Oric Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.25%。截至发稿，该股报7.58美元/股，成交量7.5166万股，换手率0.11%，振幅3.63%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3460.23%、733.65%、526.63%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.，振幅分别为41.36%、40.33%、40.24%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223157a26a3bd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310223157a26a3bd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516631766","title":"Oric Pharmaceuticals, Inc.盘中异动 临近收盘快速下跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516631766?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:41","pubTimestamp":1741034475,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时41分，Oric Pharmaceuticals, Inc.股票出现异动，股价快速跳水5.23%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Celularity Inc C/Wts 16/07/2026 涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为215.94%、187.94%、164.66%，振幅较大的相关个股有Radiopharm Theranostics Limited、Entero Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为119.50%、70.53%、64.88%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc是一家临床阶段的生物制药公司。该公司的产品候选药物包括 ORIC-944、ORIC-114 和 ORIC-533。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044115989a61a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044115989a61a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514330533","title":"Oric Pharmaceuticals, Inc.盘中异动 临近收盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514330533","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514330533?lang=zh_cn&edition=full","pubTime":"2025-02-28 04:55","pubTimestamp":1740689725,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日04时55分，Oric Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.06%。截至发稿，该股报7.88美元/股，成交量67.988万股，换手率0.96%，振幅8.43%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，Pepgen Inc.、Ibio, Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为1954.27%、423.50%、197.98%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pepgen Inc.、Pds Biotechnology Corporation，振幅分别为86.14%、67.32%、55.84%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045526abdfc290&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228045526abdfc290&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857703","title":"小摩：维持ORIC Pharmaceuticals(ORIC.US)评级，由增持调整至增持评级, 目标价由21.00美元调整至22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857703","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514857703?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:23","pubTimestamp":1740587009,"startTime":"0","endTime":"0","summary":"小摩：维持ORIC Pharmaceuticals(ORIC.US)评级，由增持调整至增持评级, 目标价由21.00美元调整至22.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27002348413728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514048213","title":"Oric Pharmaceuticals, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514048213","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514048213?lang=zh_cn&edition=full","pubTime":"2025-02-26 02:52","pubTimestamp":1740509529,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日02时52分，Oric Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.03%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Organovo Holdings, Inc.、Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1922.45%、1151.59%、993.55%，振幅较大的相关个股有Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp，振幅分别为241.19%、112.90%、87.83%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226025209abdcbb66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226025209abdcbb66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513621623","title":"HC Wainwright & Co.：重申ORIC Pharmaceuticals(ORIC.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至21.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513621623","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513621623?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:34","pubTimestamp":1740162872,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申ORIC Pharmaceuticals(ORIC.US)评级，由买入调整至买入评级, 目标价由21.00美元调整至21.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22023448321214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513929822","title":"Oric Pharmaceuticals, Inc.2024财年实现净利润-1.28亿美元，同比减少26.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513929822","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513929822?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:00","pubTimestamp":1740153658,"startTime":"0","endTime":"0","summary":"2月22日，Oric Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-1.28亿美元，同比减少26.73%；其中营业收入为0.00美元，每股基本收益为-1.83美元。从资产负债表来看，Oric Pharmaceuticals, Inc.总负债33.61百万美元，其中短期债务3.18百万美元，资产负债比为0.09，流动比率为0.11。机构评级：截至2025年2月22日，当前有11家机构对Oric Pharmaceuticals, Inc.目标价做出预测，其中目标均价为19.27美元，其中最低目标价为13.00美元，最高目标价为25.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000131abd7c349&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000131abd7c349&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513529662","title":"Oric Pharmaceuticals, Inc.盘中异动 股价大涨6.02%报7.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513529662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513529662?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:32","pubTimestamp":1740148321,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时32分，Oric Pharmaceuticals, Inc.股票出现异动，股价大幅拉升6.02%。截至发稿，该股报7.92美元/股，成交量2.3812万股，换手率0.03%，振幅1.94%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Osr Holdings, Inc.、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、蓝鸟生物较为活跃，换手率分别为69.81%、62.73%、19.91%，振幅较大的相关个股有Osr Holdings, Inc.、Aspire Biopharma Holdings, Inc.、蓝鸟生物，振幅分别为17.39%、15.26%、11.05%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223201a24eb062&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223201a24eb062&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ORIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512165106","title":"Oric Pharmaceuticals, Inc.盘中异动 股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165106","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165106?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:42","pubTimestamp":1739889776,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时42分，Oric Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.02%。截至发稿，该股报8.78美元/股，成交量4.7338万股，换手率0.07%，振幅4.55%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.55%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为303.34%、108.17%、86.77%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242569889ff49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242569889ff49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ORIC","PULM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511696798","title":"Oric Pharmaceuticals, Inc.盘中异动 早盘快速上涨5.40%报8.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511696798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511696798?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:31","pubTimestamp":1739543478,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时31分，Oric Pharmaceuticals, Inc.股票出现异动，股价急速上涨5.40%。截至发稿，该股报8.72美元/股，成交量2.1421万股，换手率0.03%，振幅0.00%。Oric Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。其相关个股中，Virpax Pharmaceuticals, Inc.、Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Virpax Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为987.87%、354.42%、318.30%，振幅较大的相关个股有Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Theratechnologies Inc.、Virpax Pharmaceuticals, Inc.，振幅分别为20.20%、18.33%、15.20%。Oric Pharmaceuticals, Inc.公司简介：ORIC Pharmaceuticals Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422311996231b3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422311996231b3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRPX","ORIC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oricpharma.com","stockEarnings":[{"period":"1week","weight":-0.1179},{"period":"1month","weight":-0.2623},{"period":"3month","weight":-0.2141},{"period":"6month","weight":-0.3092},{"period":"1year","weight":0.6765},{"period":"ytd","weight":-0.0306}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ORIC Pharmaceuticals, Inc.在特拉华州注册，成立于2014年8月。该公司是临床阶段的生物制药公司，致力于通过克服癌症抵抗力来改善患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.039993},{"month":2,"riseRate":0.5,"avgChangeRate":-0.014475},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.092137},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.173514},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03951},{"month":6,"riseRate":0.666667,"avgChangeRate":0.141043},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.000511},{"month":8,"riseRate":0.666667,"avgChangeRate":0.090659},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.048915},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.0811},{"month":11,"riseRate":0.666667,"avgChangeRate":0.167402},{"month":12,"riseRate":0.5,"avgChangeRate":0.06155}],"exchange":"NASDAQ","name":"Oric Pharmaceuticals Inc.","nameEN":"Oric Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oric Pharmaceuticals Inc.(ORIC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Oric Pharmaceuticals Inc.(ORIC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Oric Pharmaceuticals Inc.,ORIC,Oric Pharmaceuticals Inc.股票,Oric Pharmaceuticals Inc.股票老虎,Oric Pharmaceuticals Inc.股票老虎国际,Oric Pharmaceuticals Inc.行情,Oric Pharmaceuticals Inc.股票行情,Oric Pharmaceuticals Inc.股价,Oric Pharmaceuticals Inc.股市,Oric Pharmaceuticals Inc.股票价格,Oric Pharmaceuticals Inc.股票交易,Oric Pharmaceuticals Inc.股票购买,Oric Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oric Pharmaceuticals Inc.(ORIC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Oric Pharmaceuticals Inc.(ORIC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}